JACKSONVILLE, Florida, May 27, 2016 /PRNewswire/ --

TapImmune,Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced it will be presenting at two financial conferences in New York City during the week of May 30 through June 3, 2016. The Company presentations will be made by Dr. John N. Bonfiglio, a TapImmune Board member and Strategic Advisor. Dr. Bonfiglio and the Company's Chairman and CEO, Dr. Glynn Wilson will be available for one-on-one meetings with investors.

• SeeThruEquity's 5th Annual Microcap Investor Conference
  Date: Tuesday, May 31, 2016
  Time: 2:00 pm
  Location: Convene at 730 3rd Avenue

• 2016 Marcum Microcap Conference
  Date:  Thursday, June 2, 2016
  Time:  3:00 pm
  Location:  Grand Hyatt at 109 East 42nd Street

About TapImmune Inc.

TapImmune Inc. is an immuno-oncology company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at http://www.tapimmune.com for details.

Forward-Looking Statement Disclaimer

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at http://www.sec.gov . The Company assumes no obligation to update the forward-looking statements.

CONTACTS:
TapImmune Inc.,
Glynn Wilson, Ph.D.
Chairman & CEO
+1-866-359-7541

SOURCE TapImmune Inc.